MedCity Pivot Podcast: How AI Can Help in Cancer
Dr. Timothy Showalter talks about how AI can be a powerful force in recommending treatment for cancer patients. He is Artera' [...]
MMAI Model Risk Stratification for NCCN Guidelines for Low, Intermediate, and High-Risk Prostate Cancer – Neal Shore, Daniel Spratt, & Alicia Morgans
Zach Klaassen hosts a multidisciplinary roundtable discussing the NCCN Prostate Cancer Guidelines with a focus on the ArteraA [...]
Predicting Response to Hormone Therapy in Prostate Cancer With a Post-Prostatectomy MMAI Model – UroToday
Zach Klaassen discusses with Todd Morgan about innovative post-prostatectomy biomarkers. Dr. Morgan presents findings on a ne [...]
NCCN 2024 Guidelines Endorse Novel Prostate Test for Precision Risk Stratification – UroToday
Rashid Sayyid and Zach Klaassen discuss the 2024 updates to the NCCN Prostate Cancer Guidelines, highlighting the emergence o [...]
Multimodal AI Informing Treatment Decisions in Advanced Prostate Cancer – Gerhardt Attard
Alicia Morgans interviews Gerhardt Attard about groundbreaking research presented at ESMO 2023, utilizing the STAMPEDE data s [...]
Dr. Parker and Dr. Attard on the utility of ArteraAI in metastatic prostate cancer
In this video, Charles Parker, MD, and Gerhardt Attard, MD, PhD, discuss notable findings from the study “External validation [...]
VIDEO: ‘Practice-changing’ AI-derived biomarker can tailor ADT in high-risk prostate cancer
In this Healio video exclusive, Andrew Armstrong, MD, discusses his presentation from the Genitourinary Cancer session at the [...]
The Artera AI Model: Advancing Personalized Medicine in Prostate Cancer Treatment | Dan Spratt & Alicia Morgans Discuss NEJM Evidence Manuscript
Dan Spratt joins Alicia Morgans in a conversation on the Artera AI multimodal artificial intelligence model manuscript publis [...]
Personalizing Prostate Cancer Therapy Using AI-based Predictive Biomarkers – Paul Nguyen
In a discussion with Alicia Morgans, Paul Nguyen highlights the advancing role of predictive biomarkers in prostate cancer tr [...]